Novel	O
immunotherapeutic	B:C0021083
strategies	I:C0021083
to	O
target	O
alloantibody	O
-	O
producing	O
B	O
and	O
plasma	O
cells	I:C0032112
in	O
transplantation	O

Novel	O
immunotherapeutic	O
strategies	I:C0021083
to	O
target	O
alloantibody	B:C0022144
-	O
producing	O
B	O
and	O
plasma	O
cells	I:C0032112
in	O
transplantation	O

Novel	O
immunotherapeutic	O
strategies	I:C0021083
to	O
target	O
alloantibody	O
-	O
producing	O
B	B:C0004561
and	O
plasma	O
cells	I:C0032112
in	O
transplantation	O

Novel	O
immunotherapeutic	O
strategies	I:C0021083
to	O
target	O
alloantibody	O
-	O
producing	O
B	O
and	O
plasma	B:C0032112
cells	I:C0032112
in	O
transplantation	O

Novel	O
immunotherapeutic	O
strategies	I:C0021083
to	O
target	O
alloantibody	O
-	O
producing	O
B	O
and	O
plasma	O
cells	I:C0032112
in	O
transplantation	B:C0040732

There	O
is	O
an	O
unmet	O
need	O
for	O
immunotherapeutic	B:C0876248
agents	I:C0876248
that	O
target	O
humoral	O
alloimmunity	O
in	O
solid	O
organ	I:C0029216
transplantation	I:C0029216
.	O

There	O
is	O
an	O
unmet	O
need	O
for	O
immunotherapeutic	O
agents	I:C0876248
that	O
target	O
humoral	O
alloimmunity	O
in	O
solid	B:C0029216
organ	I:C0029216
transplantation	I:C0029216
.	O

This	O
includes	O
sensitized	O
patients	O
with	O
preformed	O
donor	B:C0029206
-	O
specific	O
human	O
leucocyte	I:C0019721
antigen	I:C0019721
antibodies	O
and	O
patients	O
who	O
develop	O
de-novo	O
donor	O
-	O
specific	O
antibodies	O
,	O
both	O
of	O
which	O
are	O
associated	O
with	O
acute	O
and	O
chronic	O
antibody	O
-	I:C1608421
mediated	I:C1608421
rejection	I:C1608421
and	O
allograft	O
loss	O
.	O

This	O
includes	O
sensitized	O
patients	O
with	O
preformed	O
donor	O
-	O
specific	O
human	B:C0019721
leucocyte	I:C0019721
antigen	I:C0019721
antibodies	O
and	O
patients	O
who	O
develop	O
de-novo	O
donor	O
-	O
specific	O
antibodies	O
,	O
both	O
of	O
which	O
are	O
associated	O
with	O
acute	O
and	O
chronic	O
antibody	O
-	I:C1608421
mediated	I:C1608421
rejection	I:C1608421
and	O
allograft	O
loss	O
.	O

This	O
includes	O
sensitized	O
patients	O
with	O
preformed	O
donor	O
-	O
specific	O
human	O
leucocyte	I:C0019721
antigen	I:C0019721
antibodies	B:C0003241
and	O
patients	O
who	O
develop	O
de-novo	O
donor	O
-	O
specific	O
antibodies	O
,	O
both	O
of	O
which	O
are	O
associated	O
with	O
acute	O
and	O
chronic	O
antibody	O
-	I:C1608421
mediated	I:C1608421
rejection	I:C1608421
and	O
allograft	O
loss	O
.	O

This	O
includes	O
sensitized	O
patients	O
with	O
preformed	O
donor	O
-	O
specific	O
human	O
leucocyte	I:C0019721
antigen	I:C0019721
antibodies	O
and	O
patients	O
who	O
develop	O
de-novo	O
donor	B:C0029206
-	O
specific	O
antibodies	O
,	O
both	O
of	O
which	O
are	O
associated	O
with	O
acute	O
and	O
chronic	O
antibody	O
-	I:C1608421
mediated	I:C1608421
rejection	I:C1608421
and	O
allograft	O
loss	O
.	O

This	O
includes	O
sensitized	O
patients	O
with	O
preformed	O
donor	O
-	O
specific	O
human	O
leucocyte	I:C0019721
antigen	I:C0019721
antibodies	O
and	O
patients	O
who	O
develop	O
de-novo	O
donor	O
-	O
specific	O
antibodies	B:C0003241
,	O
both	O
of	O
which	O
are	O
associated	O
with	O
acute	O
and	O
chronic	O
antibody	O
-	I:C1608421
mediated	I:C1608421
rejection	I:C1608421
and	O
allograft	O
loss	O
.	O

This	O
includes	O
sensitized	O
patients	O
with	O
preformed	O
donor	O
-	O
specific	O
human	O
leucocyte	I:C0019721
antigen	I:C0019721
antibodies	O
and	O
patients	O
who	O
develop	O
de-novo	O
donor	O
-	O
specific	O
antibodies	O
,	O
both	O
of	O
which	O
are	O
associated	O
with	O
acute	O
and	O
chronic	O
antibody	B:C1608421
-	I:C1608421
mediated	I:C1608421
rejection	I:C1608421
and	O
allograft	O
loss	O
.	O

This	O
includes	O
sensitized	O
patients	O
with	O
preformed	O
donor	O
-	O
specific	O
human	O
leucocyte	I:C0019721
antigen	I:C0019721
antibodies	O
and	O
patients	O
who	O
develop	O
de-novo	O
donor	O
-	O
specific	O
antibodies	O
,	O
both	O
of	O
which	O
are	O
associated	O
with	O
acute	O
and	O
chronic	O
antibody	O
-	I:C1608421
mediated	I:C1608421
rejection	I:C1608421
and	O
allograft	B:C0040739
loss	O
.	O

In	O
this	O
review	B:C0282443
,	O
we	O
discuss	O
recent	O
progress	O
in	O
the	O
generation	O
of	O
B	O
-	I:C0004561
cell	I:C0004561
and	O
plasma	O
cell	I:C0032112
-	O
targeted	O
therapeutics	O
,	O
with	O
an	O
emphasis	O
on	O
novel	O
agents	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
recent	O
progress	O
in	O
the	O
generation	O
of	O
B	B:C0004561
-	I:C0004561
cell	I:C0004561
and	O
plasma	O
cell	I:C0032112
-	O
targeted	O
therapeutics	O
,	O
with	O
an	O
emphasis	O
on	O
novel	O
agents	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
recent	O
progress	O
in	O
the	O
generation	O
of	O
B	O
-	I:C0004561
cell	I:C0004561
and	O
plasma	B:C0032112
cell	I:C0032112
-	O
targeted	O
therapeutics	O
,	O
with	O
an	O
emphasis	O
on	O
novel	O
agents	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
recent	O
progress	O
in	O
the	O
generation	O
of	O
B	O
-	I:C0004561
cell	I:C0004561
and	O
plasma	O
cell	I:C0032112
-	O
targeted	O
therapeutics	B:C0087111
,	O
with	O
an	O
emphasis	O
on	O
novel	O
agents	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
recent	O
progress	O
in	O
the	O
generation	O
of	O
B	O
-	I:C0004561
cell	I:C0004561
and	O
plasma	O
cell	I:C0032112
-	O
targeted	O
therapeutics	O
,	O
with	O
an	O
emphasis	O
on	O
novel	O
agents	B:C0450442
.	O

To	O
deplete	O
or	O
inhibit	O
B	B:C0004561
cells	I:C0004561
,	O
B	O
-	I:C0004561
cell	I:C0004561
-	O
specific	O
mAbs	O
have	O
been	O
developed	O
,	O
including	O
CD20	O
,	O
CD22	O
,	O
CD19	O
and	O
bi-specific	O
antibodies	O
that	O
target	O
two	O
B	O
-	I:C0004561
cell	I:C0004561
antigens	O
.	O

To	O
deplete	O
or	O
inhibit	O
B	O
cells	I:C0004561
,	O
B	B:C0004561
-	I:C0004561
cell	I:C0004561
-	O
specific	O
mAbs	O
have	O
been	O
developed	O
,	O
including	O
CD20	O
,	O
CD22	O
,	O
CD19	O
and	O
bi-specific	O
antibodies	O
that	O
target	O
two	O
B	O
-	I:C0004561
cell	I:C0004561
antigens	O
.	O

To	O
deplete	O
or	O
inhibit	O
B	O
cells	I:C0004561
,	O
B	O
-	I:C0004561
cell	I:C0004561
-	O
specific	O
mAbs	B:C0003250
have	O
been	O
developed	O
,	O
including	O
CD20	O
,	O
CD22	O
,	O
CD19	O
and	O
bi-specific	O
antibodies	O
that	O
target	O
two	O
B	O
-	I:C0004561
cell	I:C0004561
antigens	O
.	O

To	O
deplete	O
or	O
inhibit	O
B	O
cells	I:C0004561
,	O
B	O
-	I:C0004561
cell	I:C0004561
-	O
specific	O
mAbs	O
have	O
been	O
developed	O
,	O
including	O
CD20	B:C0054946
,	O
CD22	O
,	O
CD19	O
and	O
bi-specific	O
antibodies	O
that	O
target	O
two	O
B	O
-	I:C0004561
cell	I:C0004561
antigens	O
.	O

To	O
deplete	O
or	O
inhibit	O
B	O
cells	I:C0004561
,	O
B	O
-	I:C0004561
cell	I:C0004561
-	O
specific	O
mAbs	O
have	O
been	O
developed	O
,	O
including	O
CD20	O
,	O
CD22	B:C0054947
,	O
CD19	O
and	O
bi-specific	O
antibodies	O
that	O
target	O
two	O
B	O
-	I:C0004561
cell	I:C0004561
antigens	O
.	O

To	O
deplete	O
or	O
inhibit	O
B	O
cells	I:C0004561
,	O
B	O
-	I:C0004561
cell	I:C0004561
-	O
specific	O
mAbs	O
have	O
been	O
developed	O
,	O
including	O
CD20	O
,	O
CD22	O
,	O
CD19	B:C0108748
and	O
bi-specific	O
antibodies	O
that	O
target	O
two	O
B	O
-	I:C0004561
cell	I:C0004561
antigens	O
.	O

To	O
deplete	O
or	O
inhibit	O
B	O
cells	I:C0004561
,	O
B	O
-	I:C0004561
cell	I:C0004561
-	O
specific	O
mAbs	O
have	O
been	O
developed	O
,	O
including	O
CD20	O
,	O
CD22	O
,	O
CD19	O
and	O
bi-specific	O
antibodies	B:C0003241
that	O
target	O
two	O
B	O
-	I:C0004561
cell	I:C0004561
antigens	O
.	O

To	O
deplete	O
or	O
inhibit	O
B	O
cells	I:C0004561
,	O
B	O
-	I:C0004561
cell	I:C0004561
-	O
specific	O
mAbs	O
have	O
been	O
developed	O
,	O
including	O
CD20	O
,	O
CD22	O
,	O
CD19	O
and	O
bi-specific	O
antibodies	O
that	O
target	O
two	O
B	B:C0004561
-	I:C0004561
cell	I:C0004561
antigens	O
.	O

To	O
deplete	O
or	O
inhibit	O
B	O
cells	I:C0004561
,	O
B	O
-	I:C0004561
cell	I:C0004561
-	O
specific	O
mAbs	O
have	O
been	O
developed	O
,	O
including	O
CD20	O
,	O
CD22	O
,	O
CD19	O
and	O
bi-specific	O
antibodies	O
that	O
target	O
two	O
B	O
-	I:C0004561
cell	I:C0004561
antigens	B:C0003320
.	O

In	O
addition	O
,	O
inhibition	O
of	O
B	B:C0004561
-	I:C0004561
cell	I:C0004561
-	O
activating	O
cytokines	O
,	O
such	O
as	O
B	O
cell	I:C1682317
-	I:C1682317
activating	I:C1682317
factor	I:C1682317
,	O
may	O
also	O
reduce	O
allo	O
-	I:C2259068
B-	I:C2259068
cell	I:C2259068
activation	I:C2259068
.	O

In	O
addition	O
,	O
inhibition	O
of	O
B	O
-	I:C0004561
cell	I:C0004561
-	O
activating	B:C1326120
cytokines	O
,	O
such	O
as	O
B	O
cell	I:C1682317
-	I:C1682317
activating	I:C1682317
factor	I:C1682317
,	O
may	O
also	O
reduce	O
allo	O
-	I:C2259068
B-	I:C2259068
cell	I:C2259068
activation	I:C2259068
.	O

In	O
addition	O
,	O
inhibition	O
of	O
B	O
-	I:C0004561
cell	I:C0004561
-	O
activating	O
cytokines	B:C0079189
,	O
such	O
as	O
B	O
cell	I:C1682317
-	I:C1682317
activating	I:C1682317
factor	I:C1682317
,	O
may	O
also	O
reduce	O
allo	O
-	I:C2259068
B-	I:C2259068
cell	I:C2259068
activation	I:C2259068
.	O

In	O
addition	O
,	O
inhibition	O
of	O
B	O
-	I:C0004561
cell	I:C0004561
-	O
activating	O
cytokines	O
,	O
such	O
as	O
B	B:C1682317
cell	I:C1682317
-	I:C1682317
activating	I:C1682317
factor	I:C1682317
,	O
may	O
also	O
reduce	O
allo	O
-	I:C2259068
B-	I:C2259068
cell	I:C2259068
activation	I:C2259068
.	O

In	O
addition	O
,	O
inhibition	O
of	O
B	O
-	I:C0004561
cell	I:C0004561
-	O
activating	O
cytokines	O
,	O
such	O
as	O
B	O
cell	I:C1682317
-	I:C1682317
activating	I:C1682317
factor	I:C1682317
,	O
may	O
also	O
reduce	O
allo	B:C2259068
-	I:C2259068
B-	I:C2259068
cell	I:C2259068
activation	I:C2259068
.	O

Plasma	B:C0032112
cells	I:C0032112
remain	O
a	O
difficult	O
therapeutic	O
target	O
,	O
but	O
inhibition	O
of	O
germinal	O
centre	I:C0282491
responses	O
via	O
costimulatory	O
blockade	O
or	O
IL21	O
neutralization	O
,	O
induction	O
of	O
plasma	O
cell	I:C0032112
apoptosis	O
using	O
proteasome	O
inhibitors	I:C1443643
or	O
disruption	O
of	O
the	O
plasma	O
cell	I:C0032112
niche	O
are	O
potential	O
avenues	O
being	O
explored	O
.	O

Plasma	O
cells	I:C0032112
remain	O
a	O
difficult	O
therapeutic	B:C0087111
target	O
,	O
but	O
inhibition	O
of	O
germinal	O
centre	I:C0282491
responses	O
via	O
costimulatory	O
blockade	O
or	O
IL21	O
neutralization	O
,	O
induction	O
of	O
plasma	O
cell	I:C0032112
apoptosis	O
using	O
proteasome	O
inhibitors	I:C1443643
or	O
disruption	O
of	O
the	O
plasma	O
cell	I:C0032112
niche	O
are	O
potential	O
avenues	O
being	O
explored	O
.	O

Plasma	O
cells	I:C0032112
remain	O
a	O
difficult	O
therapeutic	O
target	O
,	O
but	O
inhibition	O
of	O
germinal	B:C0282491
centre	I:C0282491
responses	O
via	O
costimulatory	O
blockade	O
or	O
IL21	O
neutralization	O
,	O
induction	O
of	O
plasma	O
cell	I:C0032112
apoptosis	O
using	O
proteasome	O
inhibitors	I:C1443643
or	O
disruption	O
of	O
the	O
plasma	O
cell	I:C0032112
niche	O
are	O
potential	O
avenues	O
being	O
explored	O
.	O

Plasma	O
cells	I:C0032112
remain	O
a	O
difficult	O
therapeutic	O
target	O
,	O
but	O
inhibition	O
of	O
germinal	O
centre	I:C0282491
responses	O
via	O
costimulatory	O
blockade	O
or	O
IL21	B:C0962190
neutralization	O
,	O
induction	O
of	O
plasma	O
cell	I:C0032112
apoptosis	O
using	O
proteasome	O
inhibitors	I:C1443643
or	O
disruption	O
of	O
the	O
plasma	O
cell	I:C0032112
niche	O
are	O
potential	O
avenues	O
being	O
explored	O
.	O

Plasma	O
cells	I:C0032112
remain	O
a	O
difficult	O
therapeutic	O
target	O
,	O
but	O
inhibition	O
of	O
germinal	O
centre	I:C0282491
responses	O
via	O
costimulatory	O
blockade	O
or	O
IL21	O
neutralization	O
,	O
induction	O
of	O
plasma	B:C0032112
cell	I:C0032112
apoptosis	O
using	O
proteasome	O
inhibitors	I:C1443643
or	O
disruption	O
of	O
the	O
plasma	O
cell	I:C0032112
niche	O
are	O
potential	O
avenues	O
being	O
explored	O
.	O

Plasma	O
cells	I:C0032112
remain	O
a	O
difficult	O
therapeutic	O
target	O
,	O
but	O
inhibition	O
of	O
germinal	O
centre	I:C0282491
responses	O
via	O
costimulatory	O
blockade	O
or	O
IL21	O
neutralization	O
,	O
induction	O
of	O
plasma	O
cell	I:C0032112
apoptosis	B:C0162638
using	O
proteasome	O
inhibitors	I:C1443643
or	O
disruption	O
of	O
the	O
plasma	O
cell	I:C0032112
niche	O
are	O
potential	O
avenues	O
being	O
explored	O
.	O

Plasma	O
cells	I:C0032112
remain	O
a	O
difficult	O
therapeutic	O
target	O
,	O
but	O
inhibition	O
of	O
germinal	O
centre	I:C0282491
responses	O
via	O
costimulatory	O
blockade	O
or	O
IL21	O
neutralization	O
,	O
induction	O
of	O
plasma	O
cell	I:C0032112
apoptosis	O
using	O
proteasome	B:C1443643
inhibitors	I:C1443643
or	O
disruption	O
of	O
the	O
plasma	O
cell	I:C0032112
niche	O
are	O
potential	O
avenues	O
being	O
explored	O
.	O

Plasma	O
cells	I:C0032112
remain	O
a	O
difficult	O
therapeutic	O
target	O
,	O
but	O
inhibition	O
of	O
germinal	O
centre	I:C0282491
responses	O
via	O
costimulatory	O
blockade	O
or	O
IL21	O
neutralization	O
,	O
induction	O
of	O
plasma	O
cell	I:C0032112
apoptosis	O
using	O
proteasome	O
inhibitors	I:C1443643
or	O
disruption	O
of	O
the	O
plasma	B:C0032112
cell	I:C0032112
niche	O
are	O
potential	O
avenues	O
being	O
explored	O
.	O

The	O
ultimate	O
aim	O
of	O
these	O
animal	B:C0003062
and	O
human	O
studies	I:C0178693
is	O
to	O
develop	O
agents	O
that	O
efficiently	O
target	O
humoral	O
effectors	I:C0312740
,	O
whilst	O
sparing	O
B	O
and	O
plasma	O
cells	I:C0032112
with	O
a	O
regulatory	O
capacity	O
to	O
promote	O
long	O
-	O
term	O
allograft	O
survival	O
,	O
but	O
we	O
remain	O
some	O
distance	O
away	O
from	O
this	O
goal	O
.	O

The	O
ultimate	O
aim	O
of	O
these	O
animal	O
and	O
human	B:C0178693
studies	I:C0178693
is	O
to	O
develop	O
agents	O
that	O
efficiently	O
target	O
humoral	O
effectors	I:C0312740
,	O
whilst	O
sparing	O
B	O
and	O
plasma	O
cells	I:C0032112
with	O
a	O
regulatory	O
capacity	O
to	O
promote	O
long	O
-	O
term	O
allograft	O
survival	O
,	O
but	O
we	O
remain	O
some	O
distance	O
away	O
from	O
this	O
goal	O
.	O

The	O
ultimate	O
aim	O
of	O
these	O
animal	O
and	O
human	O
studies	I:C0178693
is	O
to	O
develop	O
agents	O
that	O
efficiently	O
target	O
humoral	B:C0312740
effectors	I:C0312740
,	O
whilst	O
sparing	O
B	O
and	O
plasma	O
cells	I:C0032112
with	O
a	O
regulatory	O
capacity	O
to	O
promote	O
long	O
-	O
term	O
allograft	O
survival	O
,	O
but	O
we	O
remain	O
some	O
distance	O
away	O
from	O
this	O
goal	O
.	O

The	O
ultimate	O
aim	O
of	O
these	O
animal	O
and	O
human	O
studies	I:C0178693
is	O
to	O
develop	O
agents	O
that	O
efficiently	O
target	O
humoral	O
effectors	I:C0312740
,	O
whilst	O
sparing	O
B	B:C0004561
and	O
plasma	O
cells	I:C0032112
with	O
a	O
regulatory	O
capacity	O
to	O
promote	O
long	O
-	O
term	O
allograft	O
survival	O
,	O
but	O
we	O
remain	O
some	O
distance	O
away	O
from	O
this	O
goal	O
.	O

The	O
ultimate	O
aim	O
of	O
these	O
animal	O
and	O
human	O
studies	I:C0178693
is	O
to	O
develop	O
agents	O
that	O
efficiently	O
target	O
humoral	O
effectors	I:C0312740
,	O
whilst	O
sparing	O
B	O
and	O
plasma	B:C0032112
cells	I:C0032112
with	O
a	O
regulatory	O
capacity	O
to	O
promote	O
long	O
-	O
term	O
allograft	O
survival	O
,	O
but	O
we	O
remain	O
some	O
distance	O
away	O
from	O
this	O
goal	O
.	O

The	O
ultimate	O
aim	O
of	O
these	O
animal	O
and	O
human	O
studies	I:C0178693
is	O
to	O
develop	O
agents	O
that	O
efficiently	O
target	O
humoral	O
effectors	I:C0312740
,	O
whilst	O
sparing	O
B	O
and	O
plasma	O
cells	I:C0032112
with	O
a	O
regulatory	O
capacity	B:C0518031
to	O
promote	O
long	O
-	O
term	O
allograft	O
survival	O
,	O
but	O
we	O
remain	O
some	O
distance	O
away	O
from	O
this	O
goal	O
.	O

The	O
ultimate	O
aim	O
of	O
these	O
animal	O
and	O
human	O
studies	I:C0178693
is	O
to	O
develop	O
agents	O
that	O
efficiently	O
target	O
humoral	O
effectors	I:C0312740
,	O
whilst	O
sparing	O
B	O
and	O
plasma	O
cells	I:C0032112
with	O
a	O
regulatory	O
capacity	O
to	O
promote	O
long	O
-	O
term	O
allograft	B:C0040739
survival	O
,	O
but	O
we	O
remain	O
some	O
distance	O
away	O
from	O
this	O
goal	O
.	O

The	O
ultimate	O
aim	O
of	O
these	O
animal	O
and	O
human	O
studies	I:C0178693
is	O
to	O
develop	O
agents	O
that	O
efficiently	O
target	O
humoral	O
effectors	I:C0312740
,	O
whilst	O
sparing	O
B	O
and	O
plasma	O
cells	I:C0032112
with	O
a	O
regulatory	O
capacity	O
to	O
promote	O
long	O
-	O
term	O
allograft	O
survival	B:C0018131
,	O
but	O
we	O
remain	O
some	O
distance	O
away	O
from	O
this	O
goal	O
.	O

The	O
ultimate	O
aim	O
of	O
these	O
animal	O
and	O
human	O
studies	I:C0178693
is	O
to	O
develop	O
agents	O
that	O
efficiently	O
target	O
humoral	O
effectors	I:C0312740
,	O
whilst	O
sparing	O
B	O
and	O
plasma	O
cells	I:C0032112
with	O
a	O
regulatory	O
capacity	O
to	O
promote	O
long	O
-	O
term	O
allograft	O
survival	O
,	O
but	O
we	O
remain	O
some	O
distance	O
away	O
from	O
this	O
goal	B:C0018017
.	O

